TY  - JOUR
N2  - In order to prevent common hypersensitivity reactions to paclitaxel injections (Taxol), we previously reported an ionic liquid-mediated paclitaxel (IL-PTX)formulation with small particle size and narrow size distribution. The preliminary work showed high PTX solubility in the IL, and the formulation demonstrated similar antitumor activity to Taxol, while inducing a smaller hypersensitivity effect in in vitro cell experiments. In this study, the stability of the IL-PTX formulation was monitored by quantitative HPLC analysis, which showed that IL-PTX was more stable at 4 °C than at room temperature. The in vivo study showed that the IL-PTX formulation could be used in a therapeutic application as a biocompatible component of a drug delivery system. To assess the in-vivo biocompatibility, IL or IL-mediated formulations were administered intravenously by maintaining physiological buffered conditions (neutral pH and isotonic salt concentration). From in vivo pharmacokinetics data, the IL-PTX formulation was found to have a similar systemic circulation time and slower elimination rate compared to cremophor EL mediated paclitaxel (CrEL-PTX). Furthermore, in vivo antitumor and hypersensitivity experiments in C57BL/6 mice revealed that IL-PTX had similar antitumor activity to CrEL-PTX, but a significantly smaller hypersensitivity effect compared with CrEL-PTX. Therefore, the IL-mediated formulation has potential to be an effective and safe drug delivery system for PTX. © 2019 Elsevier B.V.
KW  - paclitaxel; antineoplastic agent; cremophor; glycerol; ionic liquid; paclitaxel
KW  -  allergic reaction; animal experiment; animal model; antineoplastic activity; area under the curve; Article; behavior change; biocompatibility; blood vessel permeability; cancer growth; cancer inhibition; cancer size; cell division; cell viability; complement activation; controlled study; drug delivery system; drug efficacy; drug elimination; drug formulation; drug retention; drug solubility; drug stability; female; follow up; high performance liquid chromatography; histamine release; hypersensitivity; in vitro study; in vivo study; mouse; nonhuman; particle size; priority journal; rate constant; survival time; animal; C57BL mouse; drug delivery system; drug hypersensitivity; intravenous drug administration; melanoma; skin tumor; tumor cell line
KW  -  Administration
KW  -  Intravenous; Animals; Antineoplastic Agents
KW  -  Phytogenic; Cell Line
KW  -  Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice
KW  -  Inbred C57BL; Paclitaxel; Skin Neoplasms
ID  - scholars11523
Y1  - 2019///
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065414856&doi=10.1016%2fj.ijpharm.2019.05.020&partnerID=40&md5=b60958bb8dae38009058c31b09a12caa
A1  - Chowdhury, M.R.
A1  - Moshikur, R.M.
A1  - Wakabayashi, R.
A1  - Tahara, Y.
A1  - Kamiya, N.
A1  - Moniruzzaman, M.
A1  - Goto, M.
JF  - International Journal of Pharmaceutics
VL  - 565
AV  - none
N1  - cited By 28
TI  - In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations
SP  - 219
SN  - 03785173
PB  - Elsevier B.V.
EP  - 226
ER  -